Dr Srinivas Kurapati MD.

Learn to lose Money, to Gain Money, is the Paradox of Money!
I am not a Sebi Registered analyst!
Tweets are not Advice!

[Dr Srinivas Kurapati MD. @Niftyzen]

My Lovely son Chinmay SaiEswar has been studying MBBS at NRI Medical College Vizag.
My Tweets are only to share my knowledge & Experience with him!
Hence Do not construe my Tweets as Buy & Sell Recommendations as I am not a SEBI registered analyst!

[Dr Srinivas Kurapati MD. @Niftyzen]

Buy SKM Egg as an omelette, not the shell: prefer stocks with proven cooking time — steady cash flows, durable margins, management who know the recipe.
Cut early like a chef: if it smells off, toss it. A little loss keeps you in the game for the next five-star meal.

we cheer for the egg’s acrobatics, but we won’t risk our whole brunch on a hatchling stunt! 😃

Anyway appreciate your sense of humour! ☺️

[Dr Srinivas Kurapati MD. @Niftyzen]

Tennis ball stocks bounce back quickly from pullbacks, signaling strength, while Eggs (stocks) splatter and fail to recover, indicating weakness.

Focus on tennis balls during downtrends for uptrend entries.
Avoid eggs to cut losses early, as they rarely recover fully—prioritize resilience over bargains.

[Dr Srinivas Kurapati MD. @Niftyzen]

Suzlon Energy [Cmp 59 Stop Loss 52]

Fundamental Strength:
ROE 40% ROCE 35%
Debt/equity 0
P/E 25 PEG 0.10
Sales Growth 36%
Profit Growth 62%
Operating Margin 16%
Cash conversion cycle 33 days

Key Strengths:
Debt elimination: Successfully wiped out ₹4,292 Cr debt (FY21) → ₹0 (FY25)
Strong order book: 5.7 GW robust order book backing growth
High ROCE/ROE: Consistently above 25-60%, indicating superior business quality

Growth Catalysts:

Wind capacity target: India's 400 GW renewable target creates massive demand
Order inflow momentum: Recent orders from Tata Power (838 MW), Zelestra (381 MW), ArcelorMittal (248 MW)
Volume leverage: Scaling from 1.5 GW (FY25) → 2.3 GW (FY26) → 3.2 GW (FY27) reduces fixed costs
Policy support: Domestic sourcing policies favoring Indian manufacturers
Vertical integration: End-to-end wind solutions (WTG + EPC + O&M) captures full value chain

Positive Signals:
Operating cash flow turned strongly positive in FY25 after FY24 negative flow
Zero debt means no interest outflow burden (interest dropped from ₹983 Cr FY21 → ₹229 Cr FY25)
Net cash flow of ₹634-686 Cr in FY25 indicates solid liquidity generation

Caveat:
CFO/PAT ratio of 0.17 suggests some earnings are non-cash (possibly exceptional items); monitor for sustainability

Suzlon is a high-quality Stock in the renewable/manufacturing sector with exceptional fundamentals (debt-free, 60%+ ROCE), strong growth (40-60% CAGR), and improving cash flows.

The stock is undervalued at current levels with a 5.7 GW order book providing 3-year visibility.

Not a Buy/Sell recommendation!

[Dr Srinivas Kurapati MD. @Niftyzen]

Emcure Pharma [Cmp 1727 Stop Loss 1500 ]

Emcure Pharma looks fundamentally strong on growth and profitability, with decent cash generation! Technically, the trend is still constructive with long base breakout in weekly time frame and a perfect VCP set up!

Fundamentals

Emcure’s latest reported metrics show a market cap of about ₹26,452 crore, ROE of 16.72%, debt-to-equity of 0.35, P/E of 32.28, and P/B of 5.58.
That combination suggests a quality growth business!

Promoter holding remains high at 77.87%, which usually signals strong promoter commitment!

Growth Drivers

The company has been growing revenue at a healthy pace, with Q4 FY25 revenue up 19.5% YoY to ₹2,116 crore and PAT up 63% to ₹197 crore, while EBITDA margin improved to 18.4%

In Q1 FY26, revenue reached ₹2,101 crore, up 15.72% YoY, and net profit rose 40.76% to ₹215 crore, with EBITDA margin at 19.23%.

For Q4 FY26, revenue rose 16.7% YoY to ₹2,469.7 crore, net profit grew 28.81% to ₹243.4 crore, and EBITDA margin expanded further to 19.7%

Management commentary highlights complex injectables and biosimilars as key future drivers, along with margin expansion and international business growth.

Cash Flow

Cash from operating activities was ₹851.71 crore in FY25, compared with ₹1,097.24 crore in FY24, so operating cash flow remains positive but has moderated .
Investing cash outflows were relatively controlled at about -₹94 crore in FY25 versus heavier outflows in earlier years, which suggests capex and investment intensity may have eased somewhat
.
Financing cash outflow was sizeable at -₹813.96 crore in FY25, which aligns with debt servicing or other financing changes, and net cash flow for FY25 was mildly negative at -₹58.30 crore .

A useful interpretation is that the business is generating cash from operations, but the overall cash profile is being pressured by financing and expansion-related needs.

Emcure looks like a good quality pharma compounder with visible operating momentum and decent balance-sheet support.

Not a Buy/Sell recommendation!

[Dr Srinivas Kurapati MD. @Niftyzen]

SKM Egg Product Ltd [Cmp:232 Stop Loss 190]

SKM Egg has strong fundamentals (low debt, high ROE, record profits) and growth visibility from expansion, which supports potential for continued outperformance.

Growth Catalysts

Record FY25 Results: Revenue ₹767 Cr, operating profit ₹163 Cr, PAT ₹102 Cr
₹400 Cr Expansion Plan: Scaling layer capacity to increase production
Export Strength: 7,126 MT exports in FY25
Large Order Inflow: Revenue visibility for several years
Asia's Largest Egg Processing Plant: Competitive advantage

Cash Flow Scenario

Strong operating cash flow from record profits
Low debt (0.51 D/E) means less cash tied up in interest payments
₹400 Cr expansion will require capital, but strong profitability supports it.

Triangle breakout in weekly Timeframe!

Not a Buy/Sell recommendatoin!

[Dr Srinivas Kurapati MD. @Niftyzen]

Acutaas Chemicals [2887]:
2x [100%] in just 8 months!
Acutaas Chemicals' stock doubled in about 8 months because of a powerful combination of strong earnings growth, margin expansion, and a thematic shift into high‑growth chemical segments like battery‑cell solvents and CDMO/Pharma intermediates.

Acutaas Chemicals showed resilience in the last one year of volatility and downtrending markets mainly because its fundamentals kept firing even when the broader index corrected, and investors treated it as a rare “growth‑plus‑quality” small‑cap in a weak environment.

Not a Buy/Sell recommendation!

[Dr Srinivas Kurapati MD. @Niftyzen]

Acutaas Chem[1414]:
Strong Buy for investors seeking 5-10x returns over 3 years, with the semiconductor JV and specialty chemicals diversification providing multiple drivers for sustained growth. The stock's current valuation offers attractive entry point for long-term wealth creation.

Expected Return Scenarios -Conservative (3 years):
4-5x returns (50-60% CAGR).

Strong Catalysts:
1.Historic Performance: Already delivered 10x revenue growth over 10 years
2.Strategic Expansion: Korean JV and semiconductor entry creating new growth vectors
3.Margin Expansion: Improving profitability with shift to high-value products
4.Industry Tailwinds: Specialty chemicals and semiconductor sectors in structural growth phase.

Key Investment Catalysts
1.Korean JV Success: Semiconductor chemicals revenue scaling to ₹2.8 billion by FY28
2.CDMO Expansion: High-margin contract manufacturing revenue growth
3.Export Growth: International market penetration in Korea, Japan, and beyond
4.Battery Chemicals: New capacity commissioning for EV/energy storage markets
.
Outstanding Growth Trajectory
Current Price: ₹1414, with 120% absolute returns in past year.
Quarterly Explosion Q1 FY26 net profit surged 217.49% YoY to ₹44.29 crores vs ₹13.95 crores.
Revenue Growth 17.3% YoY revenue increase to ₹207.24 crores in Q1 FY26.
EBITDA Expansion: Improved from 16.71% to 24.57% in Q1 FY26.
Margin Excellence: Company achieving 25% average margins with debt near zero

Historical Multibagger Performance
10-Year Revenue Growth:10x increase from ₹62 crores to ₹1,024 crore
Profit Multiplication: Annual PAT grew from ₹1 crore to ₹160 crores over 8 years
5-Year CAGR: Strong 28% revenue growth.

Strategic Growth Drivers for Multibagger Returns
1. Korean Joint Venture & Semiconductor Expansion
Indichem JV: ₹248 crores (KRW 30 billion) investment in South Korean semiconductor chemicals venture
Market Opportunity: Expected to generate ₹2.8 billion revenue by FY28.
Strategic Positioning: 75% stake in JV targeting high-growth semiconductor chemicals market
2. Operational Excellence & Expansion
FY26 Guidance: Management reaffirmed 25% revenue growth target
CapEx Investment: Strategic investments in high-value, high-margin segments
Geographic Expansion: Strengthening relationships in Korea, Japan, and export markets
Green Energy Initiative: 15.8 MW solar plant commissioned for cost optimization.

Industry Tailwinds & Market Opportunity::
Specialty Chemicals Sector Growth:
Market Size: Indian specialty chemicals grew from $27 billion (2018) to $40 billion (2023)
Growth Rate: Sector expanding at 11%+ CAGR, outpacing bulk chemicals.
Export Opportunity: Global supply chain diversification from China benefiting Indian players
Government Support: "Make in India" and PLI schemes supporting domestic manufacturing.

Semiconductor Industry Boom:
Global Demand: Exponential growth in semiconductor chemicals demand
Supply Chain Shift: Companies seeking non-Chinese, compliant partners
Strategic Timing: Acutaas positioned early in high-growth semiconductor materials market

Competitive Advantages & Moats:
Operational Strengths
Regulatory Excellence: GMP certification from Japanese authorities
Quality Focus: Premium pricing power due to compliance and quality standards
Debt-Free Structure: Nearly zero debt providing financial flexibility.
Cash Generation: Strong operating cash flows funding growth initiatives.

Strategic Positioning
R&D Pipeline: Continuous innovation in pharmaceutical intermediates and specialty chemicals
Customer Relationships: Long-term contracts and revenue visibility through CDMO model
Geographic Diversification: Reducing China dependency, expanding in Korea/Japan

Risk Assessment & Mitigation
Controlled Risks
Seasonality: Q1 typically weaker quarter, but company maintains annual guidance.
New Segment Risk: Heavy investment in semiconductors and battery chemicals
Execution Risk: Multiple growth initiatives requiring careful management.

Mitigation Factors
Proven Track Record: 10-year history of successful execution
Diversified Portfolio: Multiple revenue streams reducing single-product dependency
Strong Balance Sheet: Financial strength to weather market volatility.

Acutaas represents a high-conviction multibagger opportunity combining proven operational excellence with strategic expansion into mega-trend sectors. The company's transformation from a traditional pharmaceutical intermediates player to a diversified specialty chemicals leader, coupled with the semiconductor JV and battery chemicals expansion, positions it for exceptional wealth creation.

[Dr Srinivas Kurapati MD. @Niftyzen]

Acutaas Chemicals [2260], has shown remarkable resilience, hitting all- time highs and outperforming the Sensex with YTD gains of 31%, 1 -year returns of 90% - vastly beating Sensex declines, driven by Middle east war fears and surging oil prices!

Robust Fundamentals:
Net profit up 48% [6 positive quarters],
ROCE 21%,
Inventory turnover 5.74x,
Zero debt to equity, ensuring stability in volatility.
38% Institutional holdings, signal confidence!

Technicals show Strong Bullish momentum!

Not a Buy/sell recommendation!

[Dr Srinivas Kurapati MD. @Niftyzen]

Polycab is a strong, well-known leader in Indian wires, cables and related electrical products with solid brand recognition and scale, but it faces near-term execution and regulatory risks so any investment should weigh valuation, recent earnings trends, and risk tolerance!
Technically No clear base for safe entries: absence of a consolidation or pullback means fewer low-risk entry points; buying now increases chance of short-term pullback risk.

[Dr Srinivas Kurapati MD. @Niftyzen]

R R Kables [Cmp 2037 Stop-Loss 1850]

RR Kabel is a credible candidate for multi‑bagger‑style returns over a 3–5 year horizon, but it’s a different type of multi‑bagger — large‑cap, execution driven rather than a small‑cap “lottery” rocket. Its fundamentals are strong, the growth runway is clear ( capacity expansion + exports + FMEG), and operating cash flow is already healthy!

Consolidated ROE is in the mid‑teens (14–16%) and ROCE around 20% historically, which are very respectable for the cables sector and indicate efficient capital use.
Management is targeting margin expansion (EBIT margins toward 10–11% in the coming years) through premiumisation and mix shift.

Future growth drivers

Large, deliberate capex plan: RR Kabel is investing ₹700–1,200 crore (over FY24–FY28 window) to expand cable capacity 1.7–2.5x and scale FMEG/exports. That incremental capacity is expected to unlock substantial revenue ( the company expects several thousand crores incremental revenue when fully ramped).

Demand pillars: domestic infrastructure/power wiring, industrial & EPC demand, export expansion, and a growing FMEG business — management targets ~18–25% CAGR in these segments over the near term.
Strategy (“Project RISE”): Premium products, technology, exports, and FMEG are explicit levers to improve margins and expand addressable market.

Cash‑flow situation

Operating cash flow is solid and improving; recent years show strong operating cash generation (examples: operating cashflow ₹340–494 crore in recent years). Capex is the main use of cash; if execution and ramp go smoothly, free cash flow should improve materially post‑ramp.

Valuation & market positioning

RR Kabel trades at a premium (P/E mid‑40s; P/B high relative to sector), reflecting expectations of margin expansion and growth already priced in. That raises short‑term re‑rating risk if execution or copper input costs disappoint.

It is well‑positioned in branded / premium cables and FMEG, with scale and distribution advantages vs. many peers.

If you prefer lower volatility and steadier compounding, raise weight; it’s less explosive but more reliable.

Place a protective stop — for trending stocks at ATH, common choices are a weekly close below the breakout level, for R R Kables Cmp 2037 Stop-loss 1850

Not a Buy/Sell recommendation!

[Dr Srinivas Kurapati MD. @Niftyzen]

@nadikattuvenka1 Sorry, I am not supposed to suggest any Buy/Sell as per Sebi rules!
If you buy, please follow given Stop-loss!

[Dr Srinivas Kurapati MD. @Niftyzen]

Ram Ratna Wires[Cmp:420 Stop-Loss 370]
Ram Ratna Wires has strong multibagger potential!

Excellent growth profile: 5‑year sales CAGR around mid‑20s% and EBIT growth even higher (40%+ with some years), plus very strong ROCE (15–20%), which is classic multibagger territory if sustained.

Capacity expansion and new businesses:
New Bhiwandi plant (30,000 tonne addition), copper‑tubes plant, and expansion in Silvassa can roughly double revenue over 2–3 years, which historically is what creates multibagger stocks.

Macro tailwinds: Rising demand for enameled copper wire in EVs, HVAC, industrial equipment, and power infrastructure gives it a multi‑year demand runway rather than a one‑time spike.

Ram Ratna Wires has a strong but capex‑heavy cash‑flow profile: it generates healthy operating cash flow but is currently reinvesting a lot in capacity, so free cash flow is negative in the short term and the company is using external financing and internal accruals to fund growth.

From a BUSINESS‑FUNDAMENTAL ANGLE, Ram Ratna Wires has the growth profile of a future multibagger, especially if it delivers on capacity ramp‑up and copper‑tubes/capex payback.

From a STOCK‑PRICE ANGLE, it can still give very strong double‑digit CAGR (possibly 25–40%+ per year) over 3–5 years if execution stays clean!

A cup‑and‑handle weekly breakout plus solid fundamentals increases the probability and speed of strong upside!

Not a Buy/Sell recommendation!

[Dr Srinivas Kurapati MD. @Niftyzen]

Happy Forgings: Cmp 1445 Stop-Loss 1300.

a Cup‑and‑Handle breakout on the weekly chart in a fundamentally strong stock like Happy Forgings can be a powerful multibagger setup!

Fundamental strength

The company has shown solid operating performance: FY25 sales were about ₹1,409 crore, EBITDA about ₹444 crore, and net profit about ₹267 crore, with EBITDA margin around 28.1% and healthy ROCE near 19.4% in one valuation snapshot.

Recent management updates point to continued capacity expansion, new product wins, and diversification into PV, industrial, and heavy forgings, with one report estimating revenue/EBITDA/PAT CAGR of roughly 18%/20%/21% over FY26–28E.

The main strength is that it is not just growing sales; it is also protecting margins and expanding into higher-value products!

Cash flow scenario

Cash flow looks healthy. FY25 operating cash flow was about ₹292 crore versus net profit of about ₹267 crore, which suggests good cash conversion, and recent updates say H1 FY26 operating cash flow conversion was nearly 100%.
The company has also kept liquidity strong, around ₹315 crore in Sep 2025, and debt-equity remained below 0.1 in recent commentary, so the expansion cycle appears financially manageable!

Happy Forgings sits in the “quality‑plus‑growth anchor” not the “rocket‑style multibagger”.

Not a Buy/Sell recommendation!

[Dr Srinivas Kurapati MD. @Niftyzen]

Emmvee Photovoltaic Power Ltd[260 Stop-Loss 225]
has strong growth and fundamentals for a solar‑manufacturing play. It’s more of a high‑growth, mid‑risk stock with potential for multibagger kind of returns!

Very high growth in revenue and profit

Revenue grew 145% YoY, and PAT jumped nearly 13× in FY25 to around ₹369 crore, signaling a sharp up‑cycle in the solar module business
Recent quarters still show strong PAT growth (around +100–160% YoY) and solid OPM near 36%, indicating scalability and pricing power in the domestic market.

Massive order book and capacity expansion

Order book is around 9.4 GW (with 6.3 GW scheduled for delivery in next 12–18 months), giving strong revenue visibility.
The company has expanded to 10.3 GW module capacity and is planning a 6 GW integrated TopCon cell‑and‑module facility, which can sustain growth for several years if executed.

Strong ROE and earnings growth outlook

Expecting EPS growth around 13% per annum and revenue growth around 22% per annum, with ROE forecast to stay near 23% in a few years, which is attractive for a manufacturing stock.

Valuation vs. sector

Trading at a P/E of 16–17× vs. a highly cyclical solar sector average P/E of 64×, so it looks “cheap” on earnings!
P/B around 4.9–15.7× (depending on source) but still below many peers, reflecting growth but also some risk discount.

Successful ramp‑up of the 6 GW with stable or improving EBITDA per watt (currently compressing slightly due to pricing pressure).
Favorable policy environment (domestic content, PLI‑style support, import‑related tariffs) without a brutal China‑style price war.

Net cash flow (CFO + investing + financing) has been:
FY23: ~₹8 crore
FY24: ~₹129 crore
FY25: ~₹36 crore.

Free cash flow (FCF = CFO + capex) is still negative or barely positive because capex is so large: recent data shows FCF around –₹375 crore to –₹440 crore in recent years, indicating the company is reinvesting almost all operating cash into capacity.

Operating cash is now robust and growing faster than net profit, which is a bullish sign for fundamentals.

The company is not “burning” operating cash; instead, it is plowing profits into capacity (6 GW TopCon line, etc.), which can fuel future multibagger‑type growth if margins hold.

Upside potential: Strong if execution, margins, and policy remain supportive; moderate if there’s a margin squeeze or policy change.

Position‑sizing: Treat it as a satellite, high‑growth holding in a diversified portfolio, not a “all‑in” multibagger bet.

Time horizon: Think 5 years to let the capacity, order book, and earnings compounding work!

The IPO listed around ₹217–220 in November 2025 and then formed a consolidation base roughly in the ₹210–230 zone! Price later broke out above this range and has now pulled back to retest the breakout zone !
Cmp 260 Stop-loss 225.

Not a Buy/Sell recommendation!

[Dr Srinivas Kurapati MD. @Niftyzen]

Honasa Consumer [Cmp:340, Stop-Loss 310]
Honasa Consumer has strong growth potential over the next 3 years, and multibagger‑type returns are possible!

Fundamental growth drivers:

Revenues & earnings:
It is expected that Revenue CAGR around 12–13% per year and earnings growth of roughly 25–26% per year over the next 3 years, significantly above the broader personal‑care sector average.
Recent quarters show operating profit growth around 38–40% annually and net profit jumping close to 28% YoY, with a target to gradually expand EBITDA margins toward low‑single‑digit percentage‑point improvements.

Over the last 3 years, net income CAGR has been about 67%, while projected net‑income CAGR for the next 3 years is still very high, around 56%, implying very strong compounding if executed.

Business‑model strengths

Brand portfolio: Mamaearth dominates a large share of its revenue, while newer brands (The Derma Co, BBlunt, etc.) are growing in the mid‑ to high‑teens/20s% range, diversifying the engine of growth.

Omnichannel push: Management is aggressively expanding offline through modern trade and general trade, which should de‑risk over‑reliance on e‑commerce and improve distribution reach.

Balance sheet: The company is net‑debt‑free, which gives it flexibility to fund innovation and marketing without taking on large leverage!

Drivers that can push multibagger returns:

Faster market share capture in India’s premium baby‑care and derma‑cosmetics categories.

Successful integration of recent acquisitions (e.g., BTM Ventures) adding new male‑care and derma‑care segments.

Gradual margin improvement from scale, product mix, and controlled marketing spend.

Technically, A Long base breakout with retest of the breakout zone, which is a high‑probability bullish pattern—especially in a fundamentally strong stock like Honasa Consumer.

Given the stock’s already high valuation and rich P/E, any failure at the re‑test can trigger sharp corrections; so position sizing (5% allocation)and strict SL(310) are crucial.

Not a Buy/Sell recommendation!

[Dr Srinivas Kurapati MD. @Niftyzen]

E2E Networks (Cmp 3018, SL 2700],
a GPU cloud infrastructure provider, shows robust revenue growth from AI demand in India!

Fundamental Strength

Revenue surged 185% YoY to ₹95.6 crore in Q4 FY26, with FY26 full-year revenue up 50% to ₹2,456 million, driven by 80% GPU capacity utilization and enterprise AI adoption.However, FY26 ended with a ₹156 million net loss due to ₹51 crore depreciation (54% of Q4 revenue), causing negative ROE (-0.53%) and ROCE (-3.09%). High valuations persist at P/B 3.53x and EV/EBITDA 65x, signaling market bets on growth despite thin 6.7% PAT margins!

E2E plans GPU expansion from 3,900 to 20,000 units, targeting India's ₹10,000+ crore AI cloud market with new data centers in Noida and Chennai.

B200 cluster deployment and the 1:10 stock split act as key catalysts for E2E Networks' price action by boosting investor sentiment, liquidity, and growth narrative in the AI cloud space. High volatility (beta 1.35) suits aggressive investors!

An upside symmetrical triangle breakout in E2E Networks, signals bullish continuation, potentially driving significant price upside by confirming momentum amid AI catalysts!

Not a Buy/Sell recommendation!

[Dr Srinivas Kurapati MD. @Niftyzen]

Data Patterns[3828]:
SL 3400
Weekly cup‑and‑handle breakout plus strong fundamentals and multi‑year growth visibility, Data Patterns is a reasonable candidate for a growth‑oriented, long‑term portfolio.

Fundamental strength

Consistent growth: The company has delivered roughly 30%+ CAGR in both revenue and net profit over the last 3 years, with healthy return on equity (ROE around 15% historically, expected to improve to 19–20% in 3 years).

Strong balance sheet: Debt‑free with healthy cash reserves, and EBITDA margins in the 35–40% range, which is very robust for a mid‑cap defence electronics player.

High‑margin defence electronics: It is a vertically integrated defence electronics vendor (radar, EW, missile systems, avionics, space), with in‑house IP and design‑to‑manufacture capability, giving it pricing power and operating leverage.

Future growth drivers:

Order book and order pipeline:
The company is targeting order inflows of ₹2,000–3,000 crore over 18–24 months and has a stated ambition of ₹30,000 crore revenue in 3 years, implying very high growth assumptions if realised.

Sector tailwinds:
Indian defence capex, “Atmanirbhar Bharat” in defence electronics, and export push provide a multi‑year runway; Data Patterns is among the few private Indian players with end‑to‑end capability, so it is well‑positioned for this cycle.

Earnings and revenue are projected to grow around 20–28% per annum in the next few years, with EPS growth in a similar band.

Data Patterns looks fundamentally strong with a very favorable growth runway, so multibagger‑like returns in 3 years are possible if execution matches ambition and valuations don’t collapse.

Not a Buy/Sell recommendation!

[Dr Srinivas Kurapati MD. @Niftyzen]

HINDUSTAN COPPER[480]:
Hindustan Copper shows promising potential for multibagger returns over the next three years, driven by strong fundamentals and growth catalysts, technically appears to be finding support around the 21-week EMA during this pullback, aligning with classic trend-following patterns.

Earnings are forecasted to grow at 69.5% per annum, with revenue expanding 26.9% annually—outpacing the Indian market's 11.3% pace.
Return on equity could hit 52.4% in three years, supported by production ramps to 12 million tons by 2030-31 via mine expansions and government aid for critical minerals.

The company's shift to a Mine Development Operator model enhances scalability, while low leverage and high ROCE , position it well despite premium valuations (PEG 2.3).

High valuations may lead to corrections, with copper price volatility and operational hurdles (e.g., weather) as key threats!

Not a Buy/Sell recommendation!

[Dr Srinivas Kurapati MD. @Niftyzen]

WAR sent opportunity:

While I'm generally against bottom fishing, today's sharp decline presents an excellent buying opportunity right at the major support level around 23,800 on the Nifty.

In this dip, I'm adding to my positions in L&T, Smallcap ETF, Union Bank, IOC, and MahaBank

Buying here offers :

High reward-to-risk ratio: Prices are undervalued with limited downside, but upside potential is significant if the level holds.

Technical confirmation: High volume at support signals institutional buying, increasing reversal odds (e.g., Nifty has bounced 70-80% of the time from this level historically).

Psychological edge:
Fear-driven sell-offs create bargains in quality stocks/ETFs, aligning with value investing principles.

Not a Buy/Sell recommendation!

[Puneet Khurana @PuneetK009]

https://t.co/Dfqx1z38mO

[Dr Srinivas Kurapati MD. @Niftyzen]

MOENERGY[37] IOC[180]
The CNX Energy (Nifty Energy) index, tracking oil, gas, and power stocks, is showing strength with a recent breakout amid a broader Indian market downturn!

Energy stocks showing resilience during market falls often act as sector leaders in bull phases due to global oil stability, govt capex in infra/power, and lower crude costs boosting refiners—outperforming broader volatility.

Safe Investors can look for MOENERGY ETF[37] sl 35
My preferred Bet IOC [180] SL 160.

Not a Buy/Sell recommendation!